This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by López-Jaramillo, P. Articles by López, M. Search for Related Content PubMed PubMed Citation Articles by López-Jaramillo, P. Articles by López, M. Social Bookmarking                         What's this?

Review: The role of the L-arginine-nitric oxide pathway in preeclampsia

VILANO Group. Research Institute, Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia and Research Department, Medical School, Universidad de Santander (UDES), Bucaramanga, Colombia, joselopez{at}fcv.org, jplopezj{at}hotmail.com

William D. Arenas

VILANO Group. Research Institute, Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia

Ronald G. García

VILANO Group. Research Institute, Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia

Melvin Y. Rincon

VILANO Group. Research Institute, Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia

Marcos López

Radical Research Center, Department of Biophysics, Medical College of Wisconsin, Milwaukee, WI, USA

Preeclampsia (PE) is a major cause of maternal and perinatal mortality, especially in developing countries. Its etiology involves multiple factors, but no specific cause has been identified. Evidence suggests that clinical manifestations are caused by endothelial dysfunction. Nitric oxide (NO), which is synthesized from L-arginine in endothelial cells by the endothelial nitric oxide synthase (eNOS), provides a tonic dilator tone and regulates the adhesion of white blood cells and platelet aggregation. Alterations in the L-arginine-NO pathway have been associated with the development of PE. Various studies, reporting decreased, elevated or unchanged levels of nitrite (NO₂) and nitrate (NO₃), two end products of NO metabolism, have been published. Our group contributed to those contradictory reports describing cases of PE with both elevated and decreased levels of NO₂ and NO₃. Apparently, diminished levels of NO could be related to deficiencies in the ingestion of dietary calcium associated to low levels of plasma ionic calcium, which is crucial to the eNOS' activity. Also, low levels of NO could be associated with the presence of eNOS polymorphisms or the presence of increased levels of ADMA, the endogenous inhibitor of NO. High levels of NO associated to low levels of cGMP suggest a decreased bioactivity of NO, which is probably related to an increased degradation of NO caused by a high production of superoxide in states of infection and inflammation. The present article analyses and reviews the reported paradoxical roles of the L-arginine-NO pathway in PE and gives a possible explanation for these results.

Key Words: preeclampsia • endothelium • nitric oxide • inflammation • infection

Therapeutic Advances in Cardiovascular Disease, Vol. 2, No. 4, 261-275 (2008)
DOI: 10.1177/1753944708092277


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?